
## Brain health and the public policy challenge panel

**Moderator: Vivienne Parry** 

Science Journalist & Broadcaster

#### Sarah Lenz Lock

Senior Vice President, Policy and Brain Health, AARP





### **GCBH Members**

#### **Established Collaborative Network of 128** brain health experts (through November 2018)

- 81 members (13 Governance; 68 Issue Specialists)
- 48 Liaisons
- 21 countries represented
- 80 universities/organizations

























CHIBA UNIVERSITY

































# **Behavioral Change**



image courtesy of commonfund.nih.gov





## **Professor Sheung-Tak Cheng**

Chair, Professor of Psychology and Gerontology, The Education University of Hong Kong

# Rising poverty and dementia: challenges for researchers and policymakers

#### Sheung-Tak Cheng

Chair Professor of Psychology and Geronology, The Education University of H.K.

Honorary Professor, Department of Psychiatry, Chinese University of Hong Kong

Honorary Chair, Department of Clinical Psychology, Norwich Medical School,

University of East Anglia

Brain Health and the Public Policy Policy Challenge World Dementia Council Summit Dec 5, 2018


#### Poverty and dementia may be linked

16% of UK pensioners living in poverty (UK Poverty 2017 report)

>30% of the US homeless population made up of people aged ≥50

Poverty is unevenly distributed in the world, and is concentrated in least developed or rural areas and societies with high GINI index

Poverty can be prevalent in metropolitan cities, where it is often invisible




In a 12-year longitudinal UK study (N>6,000), older people least wealthy (bottom 20%) were 68% more likely to have dementia than those most wealthy, after controlling for education, housing, health etc. (Cadar et al., 2018, JAMA Psychiatry)

Social drift: People with dementia may have difficulty managing financial resources well and drift to lower income groups

While education is a lifelong protective factor, financial resources may offer additional protection in later life by facilitating access to nutrition, cultural activities, leisure etc.

### The 'Coffin Homes' of Hong Kong








The most rapidly growing population of coffin home residents are young people who may well be subject to the downside effects of poverty **cumulatively for a** 





# Why is it important to bring poverty and related issues to the table for discussion?

It is a growing population worldwide!

Poor (and likewise, rural, minority) people are less likely to be enrolled in epidemiological or intervention studies

Poor people etc. are less likely to have access to services, interventions, and primary or preventive healthcare

Poverty is associated with lower literacy and awareness of dementia; hence not seeing the need to do anything about the risks

Poor people etc. may find it difficult, for various reasons, to undertake lifestyle changes

They are often marginalized and socially isolated, even invisible

Women at higher risk for poverty than men

Poverty transmits across generations

Studies of this population that draw policymakers' attention are needed

#### **Dr Tarun Dua**


Programme Manager, World Health Organization



# Global Action Plan on Public Health Response to Dementia 2017-2-25

Dr. Tarun Dua
World Health Organization (WHO)

Email: <a href="mailto:duat@who.int">duat@who.int</a>
Twitter: <a href="mailto:@WHO">@WHO</a>



### WHO activities to support Member States

Tools/resources World Health Organization

Observatory (GDO)


**Global Dementia** 

Dementia as public health priority Policy guide **Dementia-friendly** Dementia awareness & friendliness toolkit Dementia risk Dementia risk reduction reduction guidelines mhGAP toolkit Dementia treatment, care & and care pathways support Support for dementia carers **i**Support GDO e-tool and Information systems for dementia platform Dementia research & innovation **R&D Blueprint** 

WHO acknowledges the financial support from Canada, the European Commission, Germany, Japan, the Netherlands, Switzerland, the UK (incl PHE) and CDC.



# **Country-level implementation**



4) Monitoring & evaluation of progress

= comprehensive,multi-facetedapproach

address policy, service delivery and health systems monitoring

aligned with strategic action areas (e.g. risk reduction, awareness, care & support)

### Dementia as a public health priority

### Dementia awareness and friendliness

### Dementia risk reduction

#### Dementia diagnosis, treatment & care





By 2025, **75%** of countries have national policies, strategies, plans or frameworks for dementia



By 2025, 100% of countries have a functioning publicawareness campaign on dementia

By 2025, **50%** of countries have at least one dementia-friendly initiative



Risk reduction targets identified in the Global action plan for prevention and control of noncommunicable diseases 2013-2020 are achieved



By 2025, 50% of people with dementia are diagnosed, in at least 50% of countries

### Support for dementia carers



By 2025, **75**% of countries provide support and training for carers and families

### Information systems for dementia



By 2025, **50%** of countries routinely collect data on core dementia indicators

### Dementia research and innovation




Global research output on dementia doubles between 2017 and 2025



**George Vradenburg** 

Chairman, UsAgainstAlzheimer's

# Are research and drug development, and brain health related?



### **A Promising Pipeline**

PHASE 3 FACTS 2018

**Percent Change from 2017** 

PHASE 2 FACTS 2018

Percent Change from 2017

Number of Drugs: 31	<b>↓</b> -3%
Commercial Launch: 25 drugs could reach the market in the next five years	<b>↓</b> -7%
Number of Symptomatic Drugs: 12	<b>1</b> 20%
Number of Disease Modifying Drugs: 19	<b>↓</b> -14%
<b>Prevention Trials:</b> 7 drugs are in prevention trials	0%
Mechanism of Action: 14 drugs are classified as Neurotransmission	<b>1</b> 27%

<b>17</b> %
0%
<b>↓</b> -24%
<b>↑</b> 34%
0%
↑ 57% ↑ 20%

# Increasing Evidence Around Prevention and Risk Reduction




"While public health interventions will not prevent, or cure all potentially modifiable dementia, intervention for cardiovascular risk factors, mental health, and hearing may push back the onset of many people for years, **Even if some of this promise is realized, it could make a huge difference and we have already seen in some populations that dementia is being delayed for years**. Dementia prevalence could be halved if its onset were delayed by five years."

- Professor Gill Livingston, MD, from University College London and lead author of *The Lancet* Commission.

# Dementia is being diagnosed late

Perceived MCI – No Dementia




# Why is the diagnosis of the causes of cognitive impairment important?



Treat or reverse causes of cognitive decline unrelated to Alzheimer's disease



Improve health outcomes and decrease costs of care related to acute health needs



A diagnosis rate of 88% during the Mild Cognitive Impairment stage of Alzheimer's disease would result in cumulative savings of \$7.9 trillion.<sup>1</sup>



Unlock the opportunity for patients to participate in clinical trials



Enable people living with dementia to receive future disease modifying therapies earlier

### What We Can Do

Increase supply of Improve systematic Drive improved Drive through neurology and or longitudinal physician education national plans geriatric specialists screening process in primary care Drive public Spur innovation to Address insufficient improve tools for health care awareness detection and infrastructure diagnosis



#### **Perspectives**

The Shared Fight to Stop Dementias by 2025


Improving Detection and Diagnosis of Alzheimer's Disease and Related Dementias

An Urgent Call to Action for Health Care Systems Worldwide

The first in a series of white papers from the Global CEO Initiative on Alzheimer's Disease: a patient-led, private-sector coalition, and respectfully submitted to the World Health Organization as part of the cooperation agreement entered in 2018.

Authored by George Vradenburg, Cassie Dormond, and Drew Holzapfel With special thanks to the contributions of the World Health Organization Working Group of the Global CEO Initiative on Alzheimer's Disease:

David Digby, Abbvie; Marybeth Howlett,
Avid Radiopharmaceuticals; Samantha Budd & Karin Hellsvik,
Biogen; Beyhan Zaim, Pisai; Richard Johnson, Global Helix;
Pyllis Barkman Ferrell, Lilly; Vreni Schoenenberger, Novartis;
Mary Michael, Otsuka; Maurits-Jan Prinz, Rocke;
Musseini Manji, Janssen Research & Development





**Jeremy Hughes** 

CEO, Alzheimer's Society





62% would think 'life is over'

2.8 million / 15.8 million

• 25% increase in diagnosis



- Government
- Civil Society
- Business
- Researchers


















# **Questions?**